HSDT vs. BTCY, AEMD, CHEK, ICU, POAI, NURO, CUTR, MHUA, ALUR, and STRR
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include Biotricity (BTCY), Aethlon Medical (AEMD), Check-Cap (CHEK), SeaStar Medical (ICU), Predictive Oncology (POAI), NeuroMetrix (NURO), Cutera (CUTR), Meihua International Medical Technologies (MHUA), Allurion Technologies (ALUR), and Star Equity (STRR). These companies are all part of the "medical equipment" industry.
Helius Medical Technologies vs.
Biotricity (NASDAQ:BTCY) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Biotricity has a net margin of -97.05% compared to Helius Medical Technologies' net margin of -1,764.74%. Biotricity's return on equity of 0.00% beat Helius Medical Technologies' return on equity.
Helius Medical Technologies has lower revenue, but higher earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Helius Medical Technologies has a consensus price target of $24.00, suggesting a potential upside of 3,095.74%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Biotricity.
Helius Medical Technologies received 20 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 55.56% of users gave Helius Medical Technologies an outperform vote while only 0.00% of users gave Biotricity an outperform vote.
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 18.6% of Helius Medical Technologies shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 5.1% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Biotricity and Biotricity both had 1 articles in the media. Biotricity's average media sentiment score of 0.00 beat Helius Medical Technologies' score of -0.50 indicating that Biotricity is being referred to more favorably in the media.
Biotricity has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Summary
Helius Medical Technologies beats Biotricity on 11 of the 17 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:HSDT) was last updated on 1/21/2025 by MarketBeat.com Staff
